Oxford AHSN Recognizes the SGC with Its Annual Public-Private Collaboration Award
Pioneering work to accelerate drug discovery earned the SGC the 2016 Oxford Academic Health Science Network (Oxford AHSN) collaboration award.
Boston, MA, October 11, 2016 --(PR.com)-- The Structural Genomics Consortium (SGC), a precompetitive public-private partnership that accelerates research in human biology and drug discovery through open science, has won the 2016 Oxford AHSN Public-Private Collaboration Award.
The award celebrates an innovative public-private collaboration among universities, industry and the National Health Service (NHS) that ultimately benefits patients. The award was presented by Dr. Paul Durrands, COO of the Oxford AHSN, during the Oxford Biotechnology Network (OBN) awards night on 6 October. He said, “This was undoubtedly the strongest shortlist we have had in the three years we’ve been running this award. There is some great work going on in our region with real potential to make a difference to patients locally, nationally and internationally.”
Chas Bountra, Director of SGC Oxford, Dr. Wen Hwa Lee, Director Disease Foundations Network and Strategic Alliances SGC, and Dr. Rab Prinjha from the GSK Medicines Research Centre accepted the award for the SGC. Prof. Bountra said, “The AHSN concept is superb – bringing together clinicians, researchers, innovators and entrepreneurs from across the local universities, hospitals and industries to help translate our ideas into benefits for patients, the NHS and the UK economy. We in the SGC feel privileged to work with such passionate colleagues and leaders. They are helping us to accelerate the exploitation of our pre-competitive outputs and define the benefits of open-access science for all the stakeholders.”
The SGC was the unanimous winner chosen by an independent panel of judges comprising Dr. Nick Edwards, Chair of MedInnovate and Oxford AHSN Wealth Creation Oversight Group, Chris Goard, Non-Executive Director for Oxford University Hospitals NHS Foundation Trust, Charles Swingland, co-founder of Circassia, Deputy Chairman and General Counsel of Drayson Technologies, and Nigel Tipple, Chief Executive of Oxfordshire Local Enterprise Partnership.
The judges noted that the SGC’s initiatives were of “significant scope and scale” and “could make a significant difference.”
The award celebrates an innovative public-private collaboration among universities, industry and the National Health Service (NHS) that ultimately benefits patients. The award was presented by Dr. Paul Durrands, COO of the Oxford AHSN, during the Oxford Biotechnology Network (OBN) awards night on 6 October. He said, “This was undoubtedly the strongest shortlist we have had in the three years we’ve been running this award. There is some great work going on in our region with real potential to make a difference to patients locally, nationally and internationally.”
Chas Bountra, Director of SGC Oxford, Dr. Wen Hwa Lee, Director Disease Foundations Network and Strategic Alliances SGC, and Dr. Rab Prinjha from the GSK Medicines Research Centre accepted the award for the SGC. Prof. Bountra said, “The AHSN concept is superb – bringing together clinicians, researchers, innovators and entrepreneurs from across the local universities, hospitals and industries to help translate our ideas into benefits for patients, the NHS and the UK economy. We in the SGC feel privileged to work with such passionate colleagues and leaders. They are helping us to accelerate the exploitation of our pre-competitive outputs and define the benefits of open-access science for all the stakeholders.”
The SGC was the unanimous winner chosen by an independent panel of judges comprising Dr. Nick Edwards, Chair of MedInnovate and Oxford AHSN Wealth Creation Oversight Group, Chris Goard, Non-Executive Director for Oxford University Hospitals NHS Foundation Trust, Charles Swingland, co-founder of Circassia, Deputy Chairman and General Counsel of Drayson Technologies, and Nigel Tipple, Chief Executive of Oxfordshire Local Enterprise Partnership.
The judges noted that the SGC’s initiatives were of “significant scope and scale” and “could make a significant difference.”
Contact
The SGC
Amy Donner
857-231-0500
www.thesgc.org
Amy Donner
857-231-0500
www.thesgc.org
Contact
Categories